Citations

Clear

6411 citation(s) found for "Ma, Christopher".

Patient Throughput Benefits of Triage Liaison Providers Are Lost in a Resource‐neutral Model: A Prospective Trial
Nestler, David M. , Halasy, Michael , Fratzke, Alesia R., Church, Christopher J., Scanlan‐Hanson, Lori N. , Lohse, Christine M. , Campbell, Ronna L. , Sadosty, Annie T., Hess, Erik P. , Campbell, Ronna L

Mayo Clinic

Academic Emergency Medicine | June 10, 2014 | Volume: 21 | Issue: 7 | Pages: 794-798

10.1111/acem.12416 | PMID 24916989 Get It

AbstractObjectivesPatient throughput is an increasingly important cause of emergency department (ED) crowding. The authors previously reported shorter patient length of stay (LOS) when adding a triage liaison provider, which required additional personnel. Here, the objective was to evaluate the effect of moving a fast‐track provider to the triage liaison role.MethodsThis was a prospective observational before‐and‐after study design with predefined outcomes measures. A “standard staffing” situation (where an advanced practice provider staffed treatment rooms in the fast track) was compared with an advanced practice provider performing the triage liaison staffing role, with no additional staff. Eleven intervention (“triage liaison staffing”) days were compared with 11 matched control (“standard staffing”) days immediately preceding the intervention. Total LOS was measured for all adult Emergency Severity Index (ESI) 3, 4, and 5 patients (excluding behavioral health patients), and results were compared using Wilcoxon rank‐sum and chi‐square tests.ResultsA total of 681 patients registered on control days and 599 on intervention days. There was no significant difference in total patient LOS: median = 273 minutes, interquartile range (IQR) 176 to 384 minutes on intervention days versus median = 253 minutes, IQR = 175 to 365 minutes on control days (p = 0.20). There was no difference in left‐without‐being‐seen (LWBS) rates (n = 48, 7% on control days vs. n = 35, 6% on intervention days; p=0.38). Secondary analysis of only ESI 3 patients showed no difference in total LOS between periods (median = 284 minutes, IQR = 194 to 396 minutes on intervention days vs. median = 290 minutes, IQR = 217 to 397 minutes on control days; p = 0.22). There was, however, significantly greater total LOS for ESI 4 and 5 patients during the intervention period (median = 238 minutes, IQR = 124 to 350 minutes on intervention days vs. median = 192 minutes, IQR = 124 to 256 minutes on control days; p = 0.011).ConclusionsThe previously reported benefits on patient LOS and LWBS rates after adding a triage liaison (resource additive) were lost when that provider was moved from fast track to the triage role (resource neutral). While the triage liaison provider role may be a way to improve ED throughput when additional resources are available, as evidenced by our prior study, the triage liaison model itself does not appear to replace the staffing of treatment rooms, as evidenced by this study.
Transvenous Stimulation of the Renal Sympathetic Nerves Increases Systemic Blood Pressure: A Potential New Treatment Option for Neurocardiogenic Syncope
Madhavan, Malini , Ebrille, Elisa , Mulpuru, Siva K. , Mikell, Susan B. , Johnson, Susan B., Suddendorf, Scott H., Ladewig, Dorothy J., Gilles, Emily J., Danielsen, Andrew J., Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 5, 2014 | Volume: 25 | Issue: 10 | Pages: 1115-1118

10.1111/jce.12466 | PMID 24902981 Get It

Renal Vein Stimulation Increases Blood PressureBackgroundNeurocardiogenic syncope (NCS) is a common and sometimes debilitating disorder, with no consistently effective treatment. NCS is due to a combination of bradycardia and vasodilation leading to syncope. Although pacemaker devices have been tried in treating the bradycardic aspect of NCS, no device‐based therapy exists to treat the coexistent vasodilation that occurs. The renal sympathetic innervation has been the target of denervation to treat hypertension. We hypothesized that stimulation of the renal sympathetic nerves can increase blood pressure and counteract vasodilation in NCS.Methods and ResultsHigh‐frequency stimulation (800–900 pps, 10 V, 30–200 seconds) was performed using a quadripolar catheter in the renal vein of 7 dogs and 1 baboon. A significant increase in blood pressure (BP; mean [SD] systolic BP 117 [±28] vs. 128 [±33], diastolic BP 75 [±19] vs. 87 [±29] mmHg) was noted during the stimulation, which returned to baseline after cessation of stimulation. The mean increase in systolic and diastolic BP was 13.0 (±3.3) (P = 0.006) and 10.2 (±4.6) (P = 0.08), respectively.ConclusionWe report the first ever study of feasibility and safety of high‐frequency electrical stimulation of the renal sympathetic innervation to increase BP in animal models. This has potential applications in the treatment of hypotensive states such as NCS.
Mistaken identity: normotensive scleroderma renal crisis
Aburizik, Arwa , Singh, Siddharth , Al‐Rabadi, Laith , Blosser, Christopher D. , Aburizik, Arwa

Mayo Clinic

BMJ Case Reports | May 29, 2014 | Volume: 2014 | Issue: No issue available | Pages: bcr2013202566

10.1136/bcr-2013-202566 | PMID 24876209 Get It

A patient presented with neuromuscular, respiratory and cardiac symptoms and was initially diagnosed with amyotrophic lateral sclerosis (ALS), myocardial ischaemia and pneumonia. He developed unexplained progressive kidney failure over the ensuing week, and his kidney biopsy showed thrombotic microangiopathy that led to the correct diagnosis of normotensive scleroderma renal crisis. His clinical presentation and course were consistent with systemic sclerosis and normotensive scleroderma renal crisis. He was treated with an ACE inhibitor (ACEi) and haemodialysis with significant functional improvement over the next 3 months to his prior baseline with the exception of kidney failure. This case highlights a diagnostic challenge requiring astute history and physical examination skills, and the value of a kidney biopsy in providing the final diagnosis.
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
Claus, Rainer , Lucas, David , Ruppert, Amy S. , Williams, Katie , Weng, Daniel , Patterson, Kara, Zucknick, Manuela , Oakes, Christopher C. , Rassenti, Laura Z., Greaves, Andrew, Geyer, Susan M. , Brown, Jennifer R. , Barrientos, Jacqueline C. , Rai, Kanti R., Shields, Peter G. , Zhao, Weiqiang , Grever, Michael R. , Plass, Christoph , Byrd, John C. , Byrd, John C. , Wierda, William G. , Gribben, John G. , Rai, Kanti R., Kay, Neil E. , Kipps, Thomas J. , Barrientos, Jacqueline , Byrd, John C

Mayo Clinic

Blood | May 28, 2014 | Volume: 124 | Issue: 1 | Pages: 42-48

10.1182/blood-2014-02-555722 | PMID 24868078 Get It

Key Points Methylation analysis at ZAP-70 CpG+223 in CLL provides superior prognostic information vs IGHV status or CD38 or ZAP-70 expression. A pyrosequencing method for the feasible assessment of CpG+223 methylation in CLL samples is provided.
Effect of β 2 -adrenergic receptor polymorphisms on epinephrine and exercise-stimulated lipolysis in humans
Du, Shichun , Joyner, Michael J. , Curry, Timothy B. , Eisenach, John H., Johnson, Christopher P., Schrage, William G. , Jensen, Michael D. , Du, Shichun , Joyner, Michael J

Mayo Clinic

Physiological Reports | May 21, 2014 | Volume: 2 | Issue: 5 | Pages: e12017

10.14814/phy2.12017 | PMID 24844639 Get It

The past, present, and future of telemedicine for Parkinson's disease
Achey, Meredith A. , Aldred, Jason , Aljehani, Noha, Bloem, Bastiaan R. , Biglan, Kevin , Chan, Piu, Cubo, Esther , Dorsey, E. Ray , Guttman, Mark, Hassan, Anhar , Khandhar, Suketu M., Spindler, Meredith , Haak, Pieter van den , Walker, Richard , Wilkinson, Jayne , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task, Goetz, Christopher G. , Mari, Zoltan K. , Tanner, Caroline M. , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task

Mayo Clinic

Movement Disorders | May 17, 2014 | Volume: 29 | Issue: 7 | Pages: 871-883

10.1002/mds.25903 | PMID 24838316 Get It

ABSTRACT Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more‐extensive, less‐expensive participation in research. © 2014 International Parkinson and Movement Disorder Society
Neural Autoantibody Clusters Aid Diagnosis of Cancer
Horta, Erika , Lennon, Vanda A. , Jenkins, Sarah M. , McKeon, Andrew , Klein, Christopher J. , Pittock, Sean J. , Smith, Carin Y. , Lachance, Daniel Honore , Pittock, S J , Klein, Christopher J , McKeon, Andrew

Mayo Clinic

Clinical Cancer Research | May 16, 2014 | Volume: 20 | Issue: 14 | Pages: 3862-3869

10.1158/1078-0432.ccr-14-0652 | PMID 24833664 Get It

Abstract Purpose: Clustering of neural autoantibodies in patients with paraneoplastic neurologic disorders may predict tumor type. A mathematical analysis of neural autoantibody clusters was performed in 78,889 patients undergoing evaluation for a suspected paraneoplastic autoimmune neurologic disorder. Tumor predictive autoantibody profiles were confirmed in sera from patients with histologically proven tonsillar cancer, thymoma, and lung cancer. Patients and Methods: Of note, 78,889 patient sera were tested for 15 defined neural autoantibodies (1.2 million tests). The observed and hypothesized frequencies of autoantibody clusters were compared and their tumor associations defined. A tumor validation study comprised serum from 368 patients with a variety of tumors (thymoma, lung, or tonsil). Results: Informative oncological associations included (i) thymoma in 85% of patients with muscle striational, acetylcholine receptor antibodies plus CRMP5 autoantibodies; (ii) lung carcinoma in 80% with both P/Q-type and N-type calcium channel antibodies plus SOX1-IgG; and (iii) in men, prostate carcinoma frequency more than doubled when striational and muscle AChR specificities were accompanied by ganglionic AChR antibody. In women, amphiphysin-IgG alone was associated commonly with breast carcinoma, but amphiphysin-IgG, coexisting with antineuronal nuclear autoantibody-type 1 or CRMP5-IgG, was associated with lung cancer (P < 0.0001). In the validation cohorts, many tumor-associated profiles were encountered that matched the clusters identified in the screening study (e.g., 15% of thymoma patients had striational, acetylcholine receptor antibodies plus collapsin response-mediator protein-5 autoantibodies). Conclusions: Neural autoantibodies commonly coexist in specific clusters that are identifiable by comprehensive screening. Signature autoantibody clusters may predict a patient's cancer risk and type. Clin Cancer Res; 20(14); 3862–9. ©2014 AACR.
Safety and Outcomes of Magnetic Resonance Imaging in Patients with Abandoned Pacemaker and Defibrillator Leads
Higgins, John V., Gard, Joseph J., Espinosa, Raúl E. , Wood, Christopher P. , Felmlee, Joel P. , Cha, Yong‐Mei , Asirvatham, Samuel J. , Dalzell, Connie, Acker, Nancy, Watson, Robert E. , Friedman, Paul A. , Sheldon, Seth H. , Asirvatham, Samuel J

Mayo Clinic

Pacing and Clinical Electrophysiology | May 9, 2014 | Volume: 37 | Issue: 10 | Pages: 1284-1290

10.1111/pace.12419 | PMID 24809591 Get It

IntroductionAbandoned cardiovascular implantable electronic device (CIED) leads remain a contraindication to magnetic resonance imaging (MRI) studies, largely due to in vitro data showing endocardial heating secondary to the radiofrequency field. We tested the hypothesis that abandoned CIED leads do not pose an increased risk of clinical harm for patients undergoing MRI.MethodsThis single‐center retrospective study examined the outcomes of patients who had device generators removed before MRI, rendering the device leads abandoned. Information was gathered through chart review. Data collected included lead model, pacing threshold before MRI, anatomic region examined, threshold data after generator reimplantation, and clinical patient outcome.ResultsPatients (n = 19, 11 men and eight women) ranged in age from 19 to 85 at the time of MRI. There was a mean of 1.63 abandoned leads at the time of imaging; none of the leads were MRI conditional. Of the three implantable cardioverter defibrillator (ICD) leads, two of three were dual coil. Most (31/35) of the scans performed were of the central nervous system, including head and spinal imaging. There were no adverse events associated with MRI in any of these patients with abandoned leads within 7 days of the scan. No lead malfunctions or clinically significant change in pacing thresholds were noted with generator reimplantation.ConclusionThe use of MRI in patients with abandoned cardiac device leads appears feasible when performed under careful monitoring, with no adverse events, although the experience is small. MRI did not affect the function of leads that were subsequently reconnected to a cardiac device.
A Tale of Two Systems: Cardiac Cephalalgia vs Migrainous Thoracalgia
Mathew, Paul G. , Garza, Ivan , Boes, Christopher J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 6, 2014 | Volume: 55 | Issue: 2 | Pages: 310-312

10.1111/head.12373 | PMID 24801614 Get It

The practice of headache medicine is challenging, and excluding secondary causes of headaches is essential for proper diagnosis and treatment. The evaluation of secondary headaches often leads to investigations involving organ systems other than the nervous system. As such, headache, which is typically thought to be neurologic in origin, can be a manifestation of cardiac pathology in the form of cardiac cephalalgia. Conversely, chest pain, which is typically thought to be cardiac in origin, could be a manifestation of a neurologic disease process in the form of atypical migraine aura. In the presented cases, we demonstrate headaches that involve cardiac and neurologic pathology with atypical presentations.
Genetic Profiling by Single‐Nucleotide Polymorphism‐Based Array Analysis Defines Three Distinct Subtypes of Orbital Meningioma
Ho, Cheng‐Ying , Mosier, Stacy, Safneck, Janice R., Salomão, Diva R. , Miller, Neil R. , Gocke, Christopher D. , Batista, Denise , Eberhart, Charles G. , Rodríguez, Fausto J.

Mayo Clinic

Brain Pathology | April 28, 2014 | Volume: 25 | Issue: 2 | Pages: 193-201

10.1111/bpa.12150 | PMID 24773246 Get It

AbstractOrbital meningiomas can be classified as primary optic nerve sheath (ON) meningiomas, primary intraorbital ectopic (Ob) meningiomas and spheno‐orbital (Sph‐Ob) meningiomas based on anatomic site. Single‐nucleotide polymorphism (SNP)‐based array analysis with the Illumina 300K platform was performed on formalin‐fixed, paraffin‐embedded tissue from 19 orbital meningiomas (5 ON, 4 Ob and 10 Sph‐Ob meningiomas). Tumors were World Health Organization (WHO) grade I except for two grade II meningiomas, and one was NF2‐associated. We found genomic alterations in 68% (13 of 19) of orbital meningiomas. Sph‐Ob tumors frequently exhibited monosomy 22/22q loss (70%; 7/10) and deletion of chromosome 1p, 6q and 19p (50% each; 5/10). Among genetic alterations, loss of chromosome 1p and 6q were more frequent in clinically progressive tumors. Chromosome 22q loss also was detected in the majority of Ob meningiomas (75%; 3/4) but was infrequent in ON meningiomas (20%; 1/5). In general, Ob tumors had fewer chromosome alterations than Sph‐Ob and ON tumors. Unlike Sph‐Ob meningiomas, most of the Ob and ON meningiomas did not progress even after incomplete excision, although follow‐up was limited in some cases. Our study suggests that ON, Ob and Sph‐Ob meningiomas are three molecularly distinct entities. Our results also suggest that molecular subclassification may have prognostic implications.